首页> 外文OA文献 >Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)

【2h】

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)

机译：Alogliptin，一种二肽肽肽酶4抑制剂，可防止2型糖尿病患者颈动脉粥样硬化的进展：Alogliptin对糖尿病动脉粥样硬化的预防作用研究（Spead-A）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Tomoya Mita; Naoto Katakami; Hidenori Yoshii; Tomio Onuma; Hideaki Kaneto; Takeshi Osonoi; Toshihiko Shiraiwa; Keisuke Kosugi; Yutaka Umayahara; Tsunehiko Yamamoto; Hiroki Yokoyama; Nobuichi Kuribayashi; Hideaki Jinnouchi; Masahiko Gosho; Iichiro Shimomura; Hirotaka Watada;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) [J] . Mita Tomoya, Katakami Naoto, Yoshii Hidenori, Diabetes care . 2016,第1期

机译：阿格列汀，一种二肽基肽酶4抑制剂，可预防2型糖尿病患者的颈动脉粥样硬化进展：阿格列汀对糖尿病性动脉粥样硬化（SPEAD-A）的预防作用研究
2. Rationale, Design, and Baseline Characteristics of a Trial for the Prevention of Diabetic Atherosclerosis Using a DPP-4 Inhibitor: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) [J] . Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Journal of atherosclerosis and thrombosis. . 2013,第12期

机译：使用DPP-4抑制剂预防糖尿病性动脉粥样硬化的试验的原理，设计和基线特征：阿格列汀对糖尿病性动脉粥样硬化的预防作用研究（SPEAD-A）
3. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. [J] . White WB, Bakris GL, Bergenstal RM, The American heart journal . 2011,第4期

机译：用2型糖尿病和急性冠状动脉综合征（EXAMINE）患者用alogliptIN相对于carE的心血管外科检查（EXAMINE）：二肽基肽酶4抑制剂alogliptin对2型糖尿病合并急性冠脉综合征的患者的心血管安全性研究。
4. Fragment-Based Drug Design to Discover Novel Inhibitor of Dipeptidyl Peptidase-4 (DPP-4) as a Potential Drug for Type 2 Diabetes Therapy [C] . Eka Gunarti Ningsih, Muhammad Fauzi Hidayat, Usman Sumo Friend Tambunan International work-conference on bioinformatics and biomedical engineering . 2019

机译：基于片段的药物设计，发现二肽基肽酶-4（DPP-4）的新型抑制剂作为2型糖尿病治疗的潜在药物
5. Animal models of atherosclerosis: Overexpression of plasminogen activator inhibitor type 1 (PAI-1) and tissue factor in the rat carotid artery. [D] . Hasenstab, David Reinier. 1998

机译：动脉粥样硬化的动物模型：大鼠颈动脉中纤溶酶原激活物抑制剂1型（PAI-1）和组织因子的过表达。
6. Erratum. Alogliptin a Dipeptidyl Peptidase 4 Inhibitor Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148 [O] . Tomoya Mita, Naoto Katakami, Hidenori Yoshii, 2017

机译：勘误表。阿格列汀一种二肽基肽酶4抑制剂可预防2型糖尿病患者的颈动脉粥样硬化进展：阿格列汀对糖尿病性动脉硬化（SPEAD-A）的预防作用研究。糖尿病护理2016; 39：139–148
7. Rationale, Design, and Baseline Characteristics of a Trial for the Prevention of Diabetic Atherosclerosis Using a DPP-4 Inhibitor: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) [O] . Naoto Katakami, Tomoya Mita, Hidenori Yoshii, 2013

机译：使用DPP-4抑制剂预防糖尿病动脉粥样硬化的试验的理由，设计和基线特征：Alogliptin对糖尿病动脉粥样硬化（Spead-A）的预防作用研究

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)

著录项

引文网络

相似文献

相关主题

期刊订阅